Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Small Cap Alert:
A Strong Shadow Play on the Infra,
Construction and Manufacturing Cycle


Access Research

**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
**By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

MEDICO REMEDIES Share Price   (MEDI)



Here is the latest stock price and chart of MEDICO REMEDIES . For more details, see the MEDICO REMEDIES company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.

REFRESH
Live BSE Quotes May 20, 2026 (Close)
Price (Rs)45.71 Open (Rs) 44.37 High (Rs) 46.50 Low (Rs) 43.90
% Change1.69 Volume 14,682 Value (Rs) 665,113 52-Week H/L 59.00 / 31.00
Live NSE Quotes
Not listed
Change
1 Day
1.69%		1 Month
13.73%		3 Months
-0.70%		1 Year
-15.37%		5 Years (CAGR)*
50.10%

* Compound Annual Growth Rate

Valuation
EPS (Rs)* 1.40 P/E Ratio (x) 32.71 Market Cap (Rs m) 3,793.20 P/BV (x) 5.44 Dividend Yield (%) 0.00
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
Loading...
  
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new
Charts by TradingView

MEDICO REMEDIES Share Price Today:

MEDICO REMEDIES last traded price was up 1.7% to Rs 45.7 on the BSE. The total volume of shares traded was 0.0 m.

Overall, the broader S&P BSE HEALTHCARE Index was up by 0.2%. And the benchmark S&P BSE SENSEX was at 75,318.4 (up 0.2%).

Over the last 30 days, the MEDICO REMEDIES share price is up 13.7%. And over the last one year, MEDICO REMEDIES share price is down 15.4%.

The current market capitalisation of MEDICO REMEDIES stands at Rs 3,793.20 m. For more information, check out the list of top 100 companies in India in terms of market cap.

As of March 2026, company promoters held 61.38% stake in MEDICO REMEDIES , with no shares having been pledged. To know more, check out the latest shareholding pattern of MEDICO REMEDIES .

Before you go, here's an alert on MEDICO REMEDIES you may want to take note of...

Upcoming Corporate Actions for MEDICO REMEDIES

DateAnnouncementEx-Date
21-May-2026Quarterly Results-
Data Source: Equitymaster, Accord Fintech

List of All Upcoming Corporate Actions



FAQs on MEDICO REMEDIES

What is the MEDICO REMEDIES share price today?

The last traded price of MEDICO REMEDIES was Rs 45.7 on the BSE, up 1.7% over the previous close.

What is the market cap of MEDICO REMEDIES ?

The current market capitalisation of MEDICO REMEDIES stands at Rs 3,793 m. For more information, check out the list of top 100 companies in India in terms of market cap.

What is the Earnings per share (EPS) of MEDICO REMEDIES ?

MEDICO REMEDIES had an EPS of Rs 1.4 in the latest financial year.

What is the PE Ratio and PB Ratio of MEDICO REMEDIES ?

At the current price of Rs 45.7, MEDICO REMEDIES trades at a PE ratio of 32.71 while its PB ratio stands at 5.44.

Which are the top pharmaceuticals companies in India by marketcap?

Based on marketcap, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks ranked by marketcap here.

Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.

Which are the biggest pharmaceuticals companies in India by sales?

Based on sales, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks.

Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.

Which are the biggest pharmaceuticals companies in India by net profit?

Based on net profit, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks.

In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.


Today's Market

Lenskart Q4 Result | Rupee Hits Record Low | Top Buzzing Stocks Today Lenskart Q4 Result | Rupee Hits Record Low | Top Buzzing Stocks Today(Pre-Open)

Indian markets traded positive throughout the session and ultimately closed green.

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Quantum Information Services Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

  • Registered Name:

    Quantum Information Services Private Limited

  • Registered Office Address:

    103, Regent Chambers, Nariman Point, Mumbai 400021

  • CIN:

    U65990MH1989PTC054667

  • Website:

    www.equitymaster.com

  • Compliance Officer & Grievance Officer:

    Ms. Sonal Ramachandran

    | Telephone No.: +91-22-61434003 | Email: compliance@equitymaster.com

SEBI Registered Research Analyst Details:

SEBI Registration No.: INH000021128 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 6769

Principal Officer: Tanushree Banerjee | Telephone No.:+91-22-61434055 | Email: po.ra@equitymaster.com

SEBI Registered Investment Adviser Details:

SEBI Registration No.: INA000000680 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 1488

Principal Officer: Vivek Chaurasia | Telephone No.:+91-22-61434055 | Email: po.ria@equitymaster.com

SEBI Office Details:

SEBI Bhavan BKC
Address: Plot No.C4-A, 'G' Block Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra
Telephone No.: +91-22-26449000 / 40459000 | Fax: +91-22-26449019-22 / 40459019-22 | Email: sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575
SCORES: https://www.scores.gov.in/ | SMARTODR: https://smartodr.in/login

Association of Mutual Funds of India (AMFI) Registered Details:

AMFI Registered Mutual Fund Distributor
AMFI Registration Number : ARN - 1022
Date of Initial Registration : 28 / JAN / 2008
Current Validity of ARN upto : 28 / JAN / 2028

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.

Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.

The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.